TYPE 2 DIABETES MELLITUS: PATHOPHYSIOLOGY, DIAGNOSTICS, AND CONTEMPORARY THERAPEUTIC STRATEGIES. A REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5814Keywords:
Type 2 Diabetes Mellitus, Insulin Resistance, SGLT-2 Inhibitors, GLP-1 Agonists, Cardiovascular Complications, Renal ComplicationsAbstract
Type 2 diabetes mellitus (T2DM) remains one of the dominant clinical challenges in modern medicine. According to the 11th edition of the IDF Diabetes Atlas (2025), 589 million adults currently suffer from this condition, and it is estimated that by 2050, the number of patients will increase by 46%, reaching 853 million.
This paper reviews current knowledge on the pathogenesis of T2DM, which includes peripheral insulin resistance, the progressive loss of pancreatic beta-cell mass alongside secondary impairment of their secretory function, and systemic inflammation. Diagnostic criteria are presented in accordance with the 2025 PTD (Diabetes Poland) guidelines, including recommendations for screening and the identification of high-risk groups.
A fundamental part of the study is devoted to modern pharmacotherapy, with a particular focus on SGLT-2 inhibitors and GLP-1 receptor agonists as drugs with documented cardioneproprotective effects. Furthermore, the role of metabolic surgery and the importance of comprehensive, multidisciplinary care in the prevention and treatment of organ-related complications are discussed.
References
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022). Trends in insulin resistance: Insights into mechanisms and therapeutic strategy. Signal Transduction and Targeted Therapy, 7(1), 216. https://doi.org/10.1038/s41392-022-01073-0
International Diabetes Federation. (2025). IDF diabetes atlas (11th ed.). https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018). Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovascular Diabetology, 17(1), 83. https://doi.org/10.1186/s12933-018-0728-6
Petersen, M. C., & Shulman, G. I. (2018). Mechanisms of insulin action and insulin resistance. Physiological Reviews, 98(4), 2133–2223. https://doi.org/10.1152/physrev.00063.2017
Zhao, X., An, X., Yang, C., Sun, W., Ji, H., & Lian, F. (2023). The crucial role and mechanism of insulin resistance in metabolic disease. Frontiers in Endocrinology, 14, 1149239. https://doi.org/10.3389/fendo.2023.1149239
Szukiewicz, D. (2023). Molecular mechanisms for the vicious cycle between insulin resistance and the inflammatory response in obesity. International Journal of Molecular Sciences, 24(12), 9818. https://doi.org/10.3390/ijms24129818
Blüher, M. (2020). Metabolically healthy obesity. Endocrine Reviews, 41(3), bnaa004. https://doi.org/10.1210/endrev/bnaa004
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014). Novel agents for the treatment of type 2 diabetes. Diabetes Spectrum, 27(2), 100–112. https://doi.org/10.2337/diaspect.27.2.100
Lv, C., Sun, Y., Zhang, Z. Y., Aboelela, Z., Qiu, X., & Meng, Z. X. (2022). β-cell dynamics in type 2 diabetes and in dietary and exercise interventions. Journal of Molecular Cell Biology, 14(7), mjac046. https://doi.org/10.1093/jmcb/mjac046
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 52(1), 102–110. https://doi.org/10.2337/diabetes.52.1.102
Newsholme, P., Keane, K. N., Carlessi, R., & Cruzat, V. (2019). Oxidative stress pathways in pancreatic β-cells and insulin-sensitive cells and tissues: Importance to cell metabolism, function, and dysfunction. American Journal of Physiology-Cell Physiology, 317(3), C420–C433. https://doi.org/10.1152/ajpcell.00141.2019
Bishoyi, A. K., Roham, P. H., Rachineni, K., Save, S., Hazari, M. A., Sharma, S., & Kumar, A. (2020). Human islet amyloid polypeptide (hIAPP)—A curse in type II diabetes mellitus: Insights from structure and toxicity studies. Biological Chemistry, 402(2), 133–153. https://doi.org/10.1515/hsz-2020-0174
Dludla, P. V., Mabhida, S. E., Ziqubu, K., Nkambule, B. B., Mazibuko-Mbeje, S. E., Hanser, S., Basson, A. K., Pheiffer, C., & Kengne, A. P. (2023). Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World Journal of Diabetes, 14(3), 130–146. https://doi.org/10.4239/wjd.v14.i3.130
Ordovas-Montanes, J. M., & Ordovas, J. M. (2012). Cholesterol, inflammasomes, and atherogenesis. Current Cardiovascular Risk Reports, 6(1), 45–52. https://doi.org/10.1007/s12170-011-0212-2
Zhou, Z., Sun, B., Yu, D., & Zhu, C. (2022). Gut microbiota: An important player in type 2 diabetes mellitus. Frontiers in Cellular and Infection Microbiology, 12, 834485. https://doi.org/10.3389/fcimb.2022.834485
Nauck, M. A., & Müller, T. D. (2023). Incretin hormones and type 2 diabetes. Diabetologia, 66(10), 1780–1795. https://doi.org/10.1007/s00125-023-05956-x
Polskie Towarzystwo Diabetologiczne. (2025). Zalecenia kliniczne dotyczące postępowania u osób z cukrzycą – 2025: Stanowisko Polskiego Towarzystwa Diabetologicznego. https://ptdiab.pl/zalecenia-ptd/zalecenia-kliniczne-dotyczace-postepowania-u-osob-z-cukrzyca-2025
Mishra, R., Åkerlund, M., Cousminer, D. L., Ahlqvist, E., Bradfield, J. P., Chesi, A., Hodge, K. M., Guy, V. C., Brillon, D. J., Pratley, R. E., Rickels, M. R., Vella, A., Ovalle, F., Harris, R. I., Melander, O., Varvel, S., Hakonarson, H., Froguel, P., Lonsdale, J. T., Mauricio, D., … Grant, S. F. A. (2020). Genetic discrimination between LADA and childhood-onset type 1 diabetes within the MHC. Diabetes Care, 43(2), 418–425. https://doi.org/10.2337/dc19-0986
Shields, B. M., Shepherd, M., Hudson, M., McDonald, T. J., Colclough, K., Peters, J., Knight, B., Hyde, C., Ellard, S., Pearson, E. R., Hattersley, A. T., & UNITED Study Team. (2017). Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care, 40(8), 1017–1025. https://doi.org/10.2337/dc17-0224
Diabetes Prevention Program Research Group. (2015). Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology, 3(11), 866–875. https://doi.org/10.1016/S2213-8587(15)00291-0
Jannasch, F., Kröger, J., & Schulze, M. B. (2017). Dietary patterns and type 2 diabetes: A systematic literature review and meta-analysis of prospective studies. The Journal of Nutrition, 147(6), 1174–1182. https://doi.org/10.3945/jn.116.242552
Kirwan, J. P., Sacks, J., & Nieuwoudt, S. (2017). The essential role of exercise in the management of type 2 diabetes. Cleveland Clinic Journal of Medicine, 84(7 Suppl. 1), S15–S21. https://doi.org/10.3949/ccjm.84.s1.03
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B. (2022). Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 45(11), 2753–2786. https://doi.org/10.2337/dci22-0034
Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Diabetologia, 60(9), 1577–1585. https://doi.org/10.1007/s00125-017-4342-z
Zakynthinos, G. E., Tsironikos, G. I., Oikonomou, E., Kalogeras, K., Siasos, G., & Tsolaki, V. (2026). Metformin beyond glycemic control: Cardiovascular protection and diabetes prevention. Journal of Cardiovascular Development and Disease, 13(1), 33. https://doi.org/10.3390/jcdd13010033
Vallon, V., & Thomson, S. C. (2017). Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia, 60(2), 215–225. https://doi.org/10.1007/s00125-016-4157-3
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., Inzucchi, S. E., & EMPA-REG OUTCOME Investigators. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117–2128. https://doi.org/10.1056/NEJMoa1504720
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., Jamal, W., Kimura, K., Schnee, J., Zeller, C., Cotton, D., Bocchi, E., Böhm, M., Choi, D. J., Chopra, V., Chuquiure, E., … EMPEROR-Reduced Trial Investigators. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. The New England Journal of Medicine, 383(15), 1413–1424. https://doi.org/10.1056/NEJMoa2022190
Verma, S., & McMurray, J. J. V. (2018). SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia, 61(10), 2108–2117. https://doi.org/10.1007/s00125-018-4670-7
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., LEADER Steering Committee, & LEADER Trial Investigators. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., Vilsbøll, T., & SUSTAIN-6 Investigators. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., Conget, I., … REWIND Investigators. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
Holst, J. J., & Rosenkilde, M. M. (2020). GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. The Journal of Clinical Endocrinology & Metabolism, 105(8), e2710–e2716. https://doi.org/10.1210/clinem/dgaa327
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., Nishiyama, H., Nissen, S. E., Sattar, N., Weerakkody, G., Wiese, R. J., Zinman, B., Zoungas, S., Basile, J., Davies, M. J., Giorgino, F., … SURPASS-CVOT Investigators. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. The New England Journal of Medicine, 393(24), 2409–2420. https://doi.org/10.1056/NEJMoa2505928
Balasubaramaniam, V., & Pouwels, S. (2023). Remission of type 2 diabetes mellitus (T2DM) after sleeve gastrectomy (SG), one-anastomosis gastric bypass (OAGB), and Roux-en-Y gastric bypass (RYGB): A systematic review. Medicina, 59(5), 985. https://doi.org/10.3390/medicina59050985
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., le Roux, C. W., Sattar, N., Baur, L. A., Morrison, K. M., Misra, A., Kadowaki, T., Tham, K. W., Sumithran, P., Garvey, W. T., Kirwan, J. P., … Mingrone, G. (2025). Definition and diagnostic criteria of clinical obesity. The Lancet Diabetes & Endocrinology, 13(3), 221–262. https://doi.org/10.1016/S2213-8587(24)00316-4
Chaudhuri, A., Ghanim, H., & Arora, P. (2022). Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes, Obesity and Metabolism, 24(3), 365–376. https://doi.org/10.1111/dom.14601
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022). Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International, 102(2), 248–260. https://doi.org/10.1016/j.kint.2022.05.012
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., Filippatos, G., & FIDELIO-DKD Investigators. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. The New England Journal of Medicine, 383(23), 2219–2229. https://doi.org/10.1056/NEJMoa2025845
Wang, Z., Zhang, N., Lin, P., Xing, Y., & Yang, N. (2024). Recent advances in the treatment and delivery system of diabetic retinopathy. Frontiers in Endocrinology, 15, 1347864. https://doi.org/10.3389/fendo.2024.1347864
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominik Wiater, Kacper Szkodziński, Inga Jakubczyk, Jagoda Maternia, Aleksandra Łoś, Karolina Majowicz-Czaszyńska, Wiktoria Pempuś, Nikola Król, Barbara Tomaszek, Aleksandra Blok, Gabriela Płodzień
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
